



University of Nebraska at Omaha  
DigitalCommons@UNO

Journal Articles

Department of Biomechanics

10-2011

# Is There a Relationship Between Fatigue Questionnaires and Gait Mechanics in Persons With Multiple Sclerosis?

Jessie M. Huisinga

*University of Nebraska at Omaha*

Mary Filipi

*University of Nebraska Medical Center*

Kendra K. Schmid

*University of Nebraska Medical Center*

Nicholas Stergiou

*University of Nebraska at Omaha, nstergiou@unomaha.edu*

Follow this and additional works at: <https://digitalcommons.unomaha.edu/biomechanicsarticles>

 Part of the [Biomechanics Commons](#)

## Recommended Citation

Huisinga, Jessie M.; Filipi, Mary; Schmid, Kendra K.; and Stergiou, Nicholas, "Is There a Relationship Between Fatigue Questionnaires and Gait Mechanics in Persons With Multiple Sclerosis?" (2011). *Journal Articles*. 103.  
<https://digitalcommons.unomaha.edu/biomechanicsarticles/103>

This Article is brought to you for free and open access by the Department of Biomechanics at DigitalCommons@UNO. It has been accepted for inclusion in Journal Articles by an authorized administrator of DigitalCommons@UNO. For more information, please contact [unodigitalcommons@unomaha.edu](mailto:unodigitalcommons@unomaha.edu).



**IS THERE A RELATIONSHIP BETWEEN FATIGUE QUESTIONNAIRES AND GAIT MECHANICS IN PERSONS WITH MULTIPLE SCLEROSIS?**

Jessie M. Huisinga<sup>1</sup>, Mary L. Filipi<sup>2</sup>, Kendra K. Schmid<sup>3</sup>, Nicholas Stergiou<sup>3,4</sup>

<sup>1</sup>Department of Neurology

Oregon Health and Science University

NSI Building, Rm 1107

505 NW 185th Ave.

Beaverton, OR 97006

<sup>2</sup>College of Nursing

University of Nebraska Medical Center

985330 Nebraska Medical Center

Omaha, NE 68198-5330

<sup>3</sup>Department of Biostatistics

College of Public Health

University of Nebraska Medical Center

Omaha, NE 68198-7850, USA

<sup>4</sup>Nebraska Biomechanics Core Facility

University of Nebraska at Omaha

6001 Dodge Street

Omaha, NE 68182, USA

Acknowledgements: Support for this work was provided by the American Society of Biomechanics Grant-in-Aid and the Nebraska Research Initiative.

Corresponding Author: Dr. Jessie Huisinga



Oregon Health and Science University

NSI Building, Rm 1107

505 NW 185th Ave.

Beaverton, OR 97006 USA

Phone: 503-418-2603

Fax: 503-418-2701

*Acknowledgements*

Support for this work was provided by the American Society of Biomechanics Grant-in-Aid and the Nebraska Research Initiative.

We certify that no party having a direct interest in the results of the research supporting this article has or will confer a benefit on us or on any organization with which we are associated AND, if applicable, we certify that all financial and material support for this research (eg, NIH or NHS grants) and work are clearly identified in the title page of the manuscript.

1 *Abstract*

2 Objective: To evaluate the reported fatigue levels and gait deficits in Multiple Sclerosis (MS)  
3 patients to determine the relationships that may exist between fatigue in MS patients and  
4 alterations in gait mechanics.

5 Design: Cross-sectional

6 Setting: Biomechanics laboratory

7 Participants: Subjects with MS (n = 32) and age- and sex-matched controls (n = 30).

8 Interventions: None

9 Main Outcome Measures: Fatigue Severity Scale (FSS), Modified Fatigue Index Scale (MFIS),  
10 and shortform SF-36 to assess fatigue and general health. Biomechanical gait analysis was  
11 performed to measure peak joint torques and powers in the sagittal plane at the ankle, knee, and  
12 hip. Correlations were performed between fatigue measures and degree of deficit within each MS  
13 patient for each joint torque and power measure.

14 Results: FSS was significantly correlated with deficits in ankle power generation at late stance  
15 and walking velocity. MFIS was significantly correlated with deficits in peak knee extensor  
16 torque and in knee power absorption at early stance. SF-36 subscales were correlated with  
17 several of the joint torque and power variables.

18 Conclusions: subjective fatigue rating scales alone should not be used as an indicator of motor  
19 disability or of disease progression as it affects the walking performance of the MS patients

20 Key words: joint torque, joint power, general health, neurological disease

21 *Introduction*

22           Fatigue is one of the most common symptoms of multiple sclerosis (MS). It is reported  
23 by up to 90% of patients and is described as an increased weakness with exercise or as the day  
24 progresses, as an abnormal constant and persistent sense of tiredness, or as fatigable weakness  
25 exacerbated by activity or heat<sup>1,23</sup>. Measurement of fatigue in MS patients is based primarily on  
26 the patient's own reports, and as a result, the measures are inherently subjective. Fatigue ratings  
27 in MS patients may be affected by the individual's performance self efficacy and altered sensory  
28 input during activity. Also, ratings may be affected if an observer rates the fatigue based on  
29 reports of decreased effort due to impaired motor control capabilities<sup>4</sup>.

30           Because fatigue is a subjectively reported symptom, there are currently no tests or  
31 objective signs allowing the clinician to quantify its severity outside of fatigue related  
32 questionnaires<sup>5</sup>. Studies to investigate relationships between fatigue scores have reported weak  
33 correlations and noted that fatigue is a multi-factorial symptom which may not be fully explained  
34 by one fatigue scale or another<sup>1,2</sup>. Additionally, changes in fatigue ratings do not correlate with  
35 changes in walking performance which led researchers to suggest monitoring reports of fatigue  
36 with more objective measures<sup>6</sup>. Lack of correlation between fatigue ratings and walking  
37 performance may exist because self-reported fatigue scales rely on subjective reporting by  
38 patients and therefore cannot differentiate an inability to generate or maintain voluntary force  
39 from an unwillingness to do so<sup>4</sup>.

40           MS fatigue symptoms are likely due to 'central fatigue' which indicates a problem with  
41 the neural drive to sustain muscle force<sup>4</sup>. Neural drive is also required to facilitate walking and  
42 thus is feasible to expect fatigue to be reflected as alterations in walking mechanics when MS  
43 patients are compared to healthy controls. This association between specific reports of fatigue  
44 and the gait mechanics of patients with MS has not previously been investigated.

45           The purpose of this study was to evaluate both the reported fatigue levels in MS patients  
46 and these patients' deficits in gait mechanics to determine whether relationships exist between  
47 fatigue in MS patients and alterations in gait mechanics. It was hypothesized that since both  
48 fatigue in MS patients and neural control of gait are mediated by supraspinal and spinal inputs<sup>4</sup>,  
49 <sup>7-9</sup>, there would be a significant relationship between reported fatigue levels and the alterations in  
50 gait mechanics of MS patients. Additionally, alterations in walking mechanics could lead to  
51 increased metabolic cost and overall greater energy expenditure during walking<sup>10,11</sup>. Thus,  
52 persons with MS who have greater alterations in walking mechanics could have greater fatigue  
53 levels. In addition to fatigue measures, general health measures were also investigated and  
54 compared to gait measures to determine whether general health perceptions of MS patients are  
55 related to gait mechanics. Because general health perceptions are likely influenced by fatigue  
56 levels, it was hypothesized that general health perceptions are also related to deficits in gait  
57 mechanics.

58 *Methods*

59           **Multiple Sclerosis patients.** The study comprised of 32 MS patients and 30 age, weight,  
60 gender and height matched healthy controls. All participants were recruited by our clinicians at  
61 the University's Medical Center Department of Neurology and through advertisements placed  
62 with the local chapter of the National Multiple Sclerosis Society. They provided informed  
63 consent in accordance with procedures approved by the University's Medical Center Institutional  
64 Review Board.

65           Inclusion criteria for patients with MS included cognitive competency to give informed  
66 consent as determined by our MS clinician (coauthor MF), age ranging from 19 years to 65  
67 years, an Expanded Disability Status Scale (EDSS) score 1 – 6.0<sup>12</sup>. There was no requirement  
68 for MS disease type for inclusion in the study. Healthy controls were age 19 to 65 years and free  
69 of any neurological, orthopaedic, or other co-morbid condition which could affect walking  
70 mechanics. Exclusion criteria for both patient with MS and healthy controls for the study  
71 included: inability to give informed consent, pregnancy or breastfeeding or within 3 months post  
72 partum at the initiation of the study, any other neurological or vestibular disorder, and any other  
73 co-morbid conditions which would affect gait mechanics. Controls were recruited from family  
74 members of MS subjects and through the community to match the overall MS group  
75 characteristics but were not matched to individual subjects.

76 **Data Collection Protocol**

77           In order to evaluate gait mechanics, joint torques and powers from the lower extremities  
78 were used to evaluate the overall joint muscular contributions and their responses during  
79 locomotion. Joint torques and powers have been used successfully to classify gait mechanics in  
80 the elderly and in patients with osteoarthritis, total joint replacement, and anterior cruciate



81 ligament deficiency<sup>13-16</sup> to make surgical decisions<sup>17</sup>, and to evaluate treatment outcomes in  
82 pathological populations<sup>18,19</sup>. For all data collections, the subjects (patients and controls)  
83 arrived at the laboratory where informed consent was obtained. Next, anthropometric data of the  
84 lower extremities was measured and reflective markers were placed according to anatomical  
85 location<sup>20</sup>. Figure 1 shows the marker set-up from the frontal plane only. Subjects walked  
86 through 10 meter walk-way equipped with an embedded force platform (Kistler 9281B, Kistler  
87 Instrumentation Corporation, Amhurst, NY) and surrounded with an 8 camera Motion Analysis  
88 system (Eagle system, Motion Analysis Corp., Santa Rosa, CA). Figure 2 shows a subject  
89 walking with a foot striking the force platform. The subject walked through the walkway from  
90 the determined starting position while

91           INSERT FIGURE 1 AND FIGURE 2

92 real-time marker position (60 Hz) and force platform (600 Hz) data was collected  
93 simultaneously. Once the trial was completed, the MS patient rested for at least one minute. The  
94 same process was then repeated at least four more times to obtain five good trials with the  
95 subject's footfall landing completely within the force plate without altering the stride. After five  
96 successful trials, the other leg was collected using the same process. Participants typically  
97 needed to complete a total of 15 walking trials in order to obtain 5 good trials on each side.  
98 Finally, the MS patients completed two fatigue specific questionnaires and a general health  
99 survey, the SF-36 questionnaire. These are described below.

## 100 **Qualitative measures**

101           *Fatigue Severity Scale.* The FSS is a method of evaluating fatigue in MS patients and in  
102 other conditions including chronic fatigue immune dysfunction syndrome and systemic lupus  
103 erythmatosis. The FSS is designed to differentiate fatigue from clinical depression, since both

104 share some of the same symptoms. The FSS questionnaire is comprised of nine statements  
105 related to the patients' subjective perception of fatigue and its consequences on everyday  
106 activities. Patients are asked to rate their level of agreement (toward seven) or disagreement  
107 (toward zero) with the nine statements. The FSS has been validated for use with MS patients  
108 where the scale demonstrated high internal consistency with a Cronbach's alpha of 0.81<sup>21</sup>.

109 *Modified Fatigue Impact Scale.* The MFIS is a modified form of the Fatigue Impact Scale  
110 based on items derived from interviews with MS patients. The scale assesses the effect of fatigue  
111 in terms of physical, cognitive, and psychosocial functioning with a 21-item questionnaire. The  
112 MFIS has been validated for use with MS patients by Kos et al<sup>22</sup> who found the overall  
113 Cronbach's alpha was 0.9223, 0.8813 for the physical, 0.9219 for the cognitive and 0.6496 for  
114 the psychosocial subscale.

115 *Short form SF-36.* Eight health domains are assessed with the SF-36: Physical Function,  
116 limitation due to Physical Health, limitation due to Emotional Problems, Energy, Mental Health,  
117 Bodily Pain, General Health, and Social Function. The SF-36 has been used extensively to  
118 evaluate and differentiate between groups of varying health status<sup>23,24</sup> and has previously been  
119 used with MS patients<sup>25,26</sup>.

## 120 **Quantitative Measures**

121 *Joint Torques & Powers.* During post processing, a low-pass second order Butterworth  
122 digital filter with a 7 Hz cutoff frequency was used to smooth the marker trajectories.  
123 Subsequently, the joint angles were calculated for the sagittal plane during the stance phase of  
124 walking based on the methods of Vaughan et al<sup>27</sup> and Nigg et al<sup>28</sup>. Joint torques were then  
125 calculated from the joint angles of the lower limb segments and the simultaneous ground reaction  
126 forces produced based on inverse dynamics<sup>29</sup>. Joint powers were calculated based on the

127 resultant joint torques and the angular velocities of the limb segments. Calculation of joint  
128 torques and powers was accomplished using custom made laboratory software generated in  
129 Matlab (The MathWorks, Inc., Natick, MA).

130 The peak values for joint extensor and flexor torque, and joint power absorption and  
131 generation (Figures 3 and 4) were identified for the ankle, knee and hip joints during the stance  
132 phase according to other gait studies on joint kinetics<sup>13, 30-32</sup>. To identify the difference between  
133 MS patients and controls for the joint torques and powers, the value for each peak joint torque  
134 and peak joint power variable (average from 5 trials) for each MS patient was subtracted from  
135 the corresponding average value of the same variable from the healthy control group (Table 3).  
136 For example, for each MS subject, the differenced joint torque and joint power variables were  
137 calculated as:

$$138 \quad d_{\text{APT}} = \text{APT}_{\text{control mean}} - \text{APT}_{\text{MS subject}}$$

139 Because control subjects were recruited as a group and not matched to individual MS subjects,  
140 this methodology allowed for identification of the differences between MS patients and the entire  
141 control group rather than single control subjects.

142 INSERT FIGURE 3 HERE

143 INSERT FIGURE 4 HERE

#### 144 **Statistical Analysis**

145 A sample of 30 MS patients and 30 matched controls yielded 80% power to detect an  
146 effect size of 0.9 for differences in gait variables between the two groups. Independent t-tests  
147 were used to compare demographic data for patients with MS to healthy controls. Pearson  
148 correlations were performed between the scores for the FSS, MFIS, each of the eight SF-36  
149 domains and each of the differenced joint torque and power parameters. All data was assessed

150 for normality (Q-Q plots) and found to be normally distributed. Analyses were performed using  
151 SPSS 16.0 statistical software (SPSS Inc, Chicago, IL) with alpha equal with 0.05. Due to the  
152 exploratory nature of this study, no adjustments were made for multiple comparisons.

153

154 *Results*

155           A total of 32 patients with MS and 30 healthy controls were included. The MS group and  
156 healthy controls did not significantly differ in terms of age and mass. None of patients with MS  
157 experienced a relapse of symptoms within 3 months of participating in the gait analysis. All of  
158 the MS subjects were on disease modifying, but not on symptom modifying therapies. The mean  
159 EDSS score for the MS group was  $2.6 \pm 0.7$  which indicates a relatively mild level of motor  
160 disability.

161           INSERT TABLE 1 HERE

162           The mean scores for the Fatigue Severity Scale (FSS), Modified Fatigue Impact Scale  
163 (MFIS) and for each subscale of the SF-36 are listed in Table 2.

164           INSERT TABLE 2 HERE

165           The FSS showed a significant relationship only with walking velocity (Table 3) and peak  
166 ankle power generation (A2) (Table 4). The MFIS showed a significant relationship only with  
167 peak knee extensor torque (Table 3) and the peak knee power absorption (K1) (Table 4). The SF-  
168 36 Physical Function subscale revealed a significant relationship with several parameters from  
169 the joint torques (4 out of 6; Table 3) and joint powers (6 out of 8; Table 4). The Limitation due  
170 to Emotional Problems and Social Function subscales each showed a significant relationship  
171 with one joint torque (Table 3) and one joint power parameter (Table 4). The Limitation due to  
172 Physical Function subscale showed a significant relationship with walking velocity (Table 3) and  
173 with one joint power parameter (Table 4). The Energy subscale showed a significant relationship  
174 with one joint power parameter (Table 4). The Bodily Pain subscale showed a significant  
175 relationship with walking velocity (Table 3), two joint torque parameters (2 out of 6; Table 3)  
176 and three joint power parameters (3 out of 8; Table 4).

177           INSERT TABLES 3 & 4 HERE

178           Importantly, all the significant relationships between the quantitative gait measures (joint  
179 torques and powers) and the fatigue scales (FSS and MFIS) were small or medium (0.1 to 0.3  
180 and 0.3 to 0.5, respectively)<sup>33</sup>. In contrast, the SF-36 physical function subscale revealed large  
181 correlations (0.5 to 1.0) with walking velocity and with the joint torque and joint power  
182 parameters (Table 3 and 4).

183

184 *Discussion*

185           This study outlines the relationship between reported fatigue levels and the deficits in  
186 joint torques and powers during overground walking in MS patients. The FSS, which specifically  
187 evaluates fatigue levels independent of depression, showed only two significant relationships  
188 out of 15 (13.3%), indicating a limited relationship with the changes that occur in the gait  
189 mechanics of patients with MS. The MFIS, which is an MS patient specific fatigue measure,  
190 showed similar results with only two significant relationships out of 15 (13.3%). It was  
191 hypothesized that fatigue and gait mechanics would reveal significant relationships because both  
192 fatigue in MS patients and gait control. Because both gait and fatigue are affected by central  
193 neural drive<sup>4,7,9</sup>, it is expected that any alterations in gait mechanics would likely contribute to  
194 fatigue. This hypothesis was shown to be only partially true with respect to the utilized fatigue  
195 scales. With respect to SF-36, the Physical Function subscale and the Bodily Pain subscale both  
196 showed relationships with the gait mechanics of patients with MS with 11 out of 15 (73.3%) and  
197 6 out of 15 (40.0%) correlations, respectively, being significant. The larger number of significant  
198 relationships with gait mechanics and the SF-36 subscales is partially in agreement with the  
199 original hypothesis that general health perceptions would be related to gait deficit measures.

200           The lack of correlations between fatigue questionnaires (FSS and MFIS) and measures of  
201 gait mechanics indicate that the use of fatigue questionnaires to infer information regarding MS  
202 patient's functional capability may be inappropriate. The SF-36 subscales focus more on specific  
203 function areas and show stronger relationship with gait mechanics. Thus, we believe that it may  
204 be possible to better represent the relationship between fatigue in MS patients and their gait  
205 mechanics by expanding the fatigue questionnaires to incorporate the effects of fatigue on  
206 specific areas of physical function as the SF-36 does.

207           The FSS was significantly and positively related with walking velocity (Table 3) and  
208 with the joint power measure A2 (Table 4). Overall, the FSS focuses on the perception of fatigue  
209 and its consequences on everyday activities, so the results indicate that the worse the MS  
210 patient's perception of fatigue was, the larger the differences in walking velocity and in power  
211 generation at the ankle (A2) during late stance between the patients and the healthy controls. The  
212 decrements in power generation at the ankle (A2) during late stance indicate that the MS patients  
213 have difficulty propelling the trunk and the leg into the swing phase and indicate that the ankle  
214 plantarflexors (soleus and gastrocnemius) are not providing sufficient power to accelerate the  
215 trunk which would result in slower walking velocity<sup>34</sup>. The significant relationship between FSS  
216 and walking velocity decrements in MS patients indicate that FSS is related primarily with the  
217 mechanisms related to forward progression during walking. Decreased walking velocity and  
218 decreased capability to maintain forward progression during walking could result in increased  
219 energy expenditure during walking<sup>35</sup> and would likely affect performance on everyday activities  
220<sup>34, 36</sup>, causing increased overall fatigue, thus demonstrating a relationship between A2 and FSS  
221 score.

222           The MFIS, which outlines the effect of fatigue in terms of physical, cognitive, and  
223 psychosocial functioning, was correlated decreased power absorption at the knee (K1) and  
224 extensor torque at the knee (KET) during early stance phase. The decreased power absorption at  
225 the knee (K1) and extensor torque at the knee (KET) indicate that MS patients have difficulty  
226 during weight acceptance in single stance and are not able to generate the necessary extensor  
227 activity to eccentrically absorb power at the knee (negative muscle) during early stance<sup>35</sup>. Loss  
228 of the high efficiency negative work at the knee could result in increased metabolic energy  
229 expenditure during gait<sup>35</sup> and a larger metabolic cost of walking for patients with MS. Because



230 MFIS shows a significant relationship with the amount of negative work being performed at the  
231 knee during early stance, we can speculate that the MFIS is related mostly with the overall  
232 energy expenditure of patients with MS during walking.

233 MS patients may be likely to perceive fatigue levels as higher since their ability to  
234 maintain forward progression is diminished and overall metabolic cost is likely increased during  
235 walking. To maintain forward progression an increase in the frequency of muscle firing would be  
236 necessary, but this could be difficult to maintain for an MS patient due to demyelination of nerve  
237 fiber and conduction block seen in structurally intact axons<sup>37</sup>. This conduction block is proposed  
238 as the primary causation of fatigue in MS patients seen during voluntary effort<sup>4</sup>. The  
239 correlations between FSS, MFIS, and the specified joint power measures may be a reflection of  
240 the theorized primary causation of fatigue in MS patients.

241 Finally, the SF-36 subscales for Physical Function and Bodily Pain, which measure  
242 overall perceptions of general health, both had negative correlations with joint parameters which  
243 indicate that as differences in the gait measures between MS patients and healthy controls  
244 increased, the perception of physical function capability decreased in MS patients and the  
245 perceptions of bodily pain increased in MS patients. These results are not surprising since Motl  
246 et al<sup>38</sup> reported that worsening MS symptoms have a direct negative relationship with self-  
247 efficacy and physical activity; hence any changes in actual physical capability levels (reflected  
248 here by joint torques and powers) would also be related to perception of physical function. The  
249 same investigators also reported that with worsening of symptoms, including an increase in  
250 bodily pain, there is a significant decrease in levels of physical activity and physical function<sup>39</sup>.  
251 Because these scales are significantly related with several of the gait measures, it is fair to report

252 that the SF-36 subscales are relatively successful in reflecting the motor disability level of MS  
253 patients.

254 Because alterations in joint torques and powers would likely cause changes in energy  
255 expenditure during walking, it is likely that there is a relationship between gait measures and  
256 fatigue in persons with MS. However, this study showed limited correlations between the FSS  
257 and MFIS with gait measures. The SF-36 subscales showed more relationships with gait  
258 measures which may indicate that the SF-36 is a better measure of overall functional status in  
259 MS patients, however, a larger follow-up study would be needed to confirm these findings. The  
260 idea that fatigue specific questionnaires may not be the best tool to reflect physical disability  
261 level has also been reported by others<sup>6,40,41</sup>. These previously published findings combined  
262 with the findings of the current study indicate that subjective fatigue rating scales alone should  
263 not be used as an indicator of motor disability or of disease progression as it affects the walking  
264 performance of the MS patients. Instead, more quantitative measures, such as gait analysis  
265 should be used to indicate the relationship between gait problems and fatigue in MS patients and  
266 to support clinical decision making.

#### 267 *Limitations*

268 Several limitations exist in this study. First, it should be noted that we included only MS patients  
269 who were ambulatory in the study. Thus, the findings of this study, in terms of usefulness of  
270 fatigue scales to indicate functional status and disability, are generalizable only to MS patients  
271 who are ambulatory without bilateral aid (EDSS < 6.0). Second, the causes of gait dysfunction in  
272 patients with MS are likely multi-factorial and this study did not attempt to differentiate which  
273 disease mechanisms, i.e. spasticity, neuropathy, muscle weakness, were specifically related to  
274 measures of fatigue and general health. Finally, reported fatigue in MS patient is also multi-

275 factorial. Specific medication, sleep patterns, and overall lifestyle influences may affect reports  
276 of fatigue. By utilizing fatigue rating scales that are well established for use with patients who  
277 have MS, this study did not seek to specify the sources of reported fatigue but only the relative  
278 MS fatigue rating and whether those ratings were related to objective and reliable measures of  
279 walking performance.

280 *References*

- 281 1. Flachenecker P, Kumpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, et al.  
282 Fatigue in multiple sclerosis: A comparison of different rating scales and correlation to clinical  
283 parameters. *Mult Scler* 2002;8:523-6.
- 284 2. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. *Arch Phys Med*  
285 *Rehabil* 1984;65:135-8.
- 286 3. Krupp LB, Christodoulou C. Fatigue in multiple sclerosis. *Curr Neurol Neurosci Rep*  
287 2001;1:294-8.
- 288 4. Vucic S, Burke D, Kiernan MC. Fatigue in multiple sclerosis: Mechanisms and management.  
289 *Clin Neurophysiol* 2010.
- 290 5. Morrow SA, Weinstock-Guttman B, Munschauer FE, Hojnacki D, Benedict RH. Subjective  
291 fatigue is not associated with cognitive impairment in multiple sclerosis: Cross-sectional and  
292 longitudinal analysis. *Mult Scler* 2009;15:998-1005.
- 293 6. Morris ME, Cantwell C, Vowels L, Dodd K. Changes in gait and fatigue from morning to  
294 afternoon in people with multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2002;72:361-5.
- 295 7. Beres-Jones JA, Harkema SJ. The human spinal cord interprets velocity-dependent afferent  
296 input during stepping. *Brain* 2004;127:2232-46.
- 297 8. Harkema SJ. Plasticity of interneuronal networks of the functionally isolated human spinal  
298 cord. *Brain Res Rev* 2008;57:255-64.
- 299 9. Courtine G, Song B, Roy RR, Zhong H, Herrmann JE, Ao Y, et al. Recovery of supraspinal  
300 control of stepping via indirect propriospinal relay connections after spinal cord injury. *Nat Med*  
301 2008;14:69-74.

- 302 10. Siegel KL, Kepple TM, Stanhope SJ. Joint moment control of mechanical energy flow during  
303 normal gait. *Gait Posture* 2004;19:69-75.
- 304 11. Donelan JM, Kram R, Kuo AD. Mechanical work for step-to-step transitions is a major  
305 determinant of the metabolic cost of human walking. *J Exp Biol* 2002;205:3717-27.
- 306 12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability  
307 status scale (EDSS). *Neurology* 1983;33:1444-52.
- 308 13. Kerrigan DC, Lee LW, Nieto TJ, Markman JD, Collins JJ, Riley PO. Kinetic alterations  
309 independent of walking speed in elderly fallers. *Arch Phys Med Rehabil* 2000;81:730-5.
- 310 14. Landry SC, McKean KA, Hubley-Kozey CL, Stanish WD, Deluzio KJ. Knee biomechanics  
311 of moderate OA patients measured during gait at a self-selected and fast walking speed. *J*  
312 *Biomech* 2007;40:1754-61.
- 313 15. Ristanis S, Stergiou N, Patras K, Tsepis E, Moraiti C, Georgoulis AD. Follow-up evaluation  
314 2 years after ACL reconstruction with bone-patellar tendon-bone graft shows that excessive tibial  
315 rotation persists. *Clin J Sport Med* 2006;16:111-6.
- 316 16. Saari T, Tranberg R, Zugner R, Uvehammer J, Karrholm J. Changed gait pattern in patients  
317 with total knee arthroplasty but minimal influence of tibial insert design: Gait analysis during  
318 level walking in 39 TKR patients and 18 healthy controls. *Acta Orthop* 2005;76:253-60.
- 319 17. Joseph B. Quantitative gait analysis in the treatment of children with cerebral palsy. *J Pediatr*  
320 *Orthop* 2007;27:718,9; author reply 719-20.
- 321 18. Georgoulis AD, Ristanis S, Chouliaras V, Moraiti C, Stergiou N. Tibial rotation is not  
322 restored after ACL reconstruction with a hamstring graft. *Clin Orthop Relat Res* 2007;454:89-94.

- 323 19. Ristanis S, Stergiou N, Patras K, Vasiliadis HS, Giakas G, Georgoulis AD. Excessive tibial  
 324 rotation during high-demand activities is not restored by anterior cruciate ligament  
 325 reconstruction. *Arthroscopy* 2005;21:1323-9.
- 326 20. Houck J, Yack HJ, Cuddeford T. Validity and comparisons of tibiofemoral orientations and  
 327 displacement using a femoral tracking device during early to mid stance of walking. *Gait Posture*  
 328 2004;19:76-84.
- 329 21. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. application  
 330 to patients with multiple sclerosis and systemic lupus erythematosus. *Arch Neurol* 1989;46:1121-  
 331 3.
- 332 22. Kos D, Kerckhofs E, Carrea I, Verza R, Ramos M, Jansa J. Evaluation of the modified  
 333 fatigue impact scale in four different european countries. *Mult Scler* 2005;11:76-80.
- 334 23. Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF36 health survey  
 335 questionnaire: An outcome measure suitable for routine use within the NHS? *BMJ*  
 336 1993;306:1440-4.
- 337 24. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.  
 338 conceptual framework and item selection. *Med Care* 1992;30:473-83.
- 339 25. Hopman WM, Coo H, Pavlov A, Day AG, Edgar CM, McBride EV, et al. Multiple sclerosis:  
 340 Change in health-related quality of life over two years. *Can J Neurol Sci* 2009;36:554-61.
- 341 26. Nogueira LA, Nobrega FR, Lopes KN, Thuler LC, Alvarenga RM. The effect of functional  
 342 limitations and fatigue on the quality of life in people with multiple sclerosis. *Arq Neuropsiquiatr*  
 343 2009;67:812-7.
- 344 27. Vaughan CL, Davis BL, O'Connor JJ. *Dynamics of human gait: 2nd ed.* 2nd ed. Cape Town,  
 345 South Africa: Kiboho Publishers; 1992.

- 346 28. Nigg BM, Cole GK, Nachbauer W. Effects of arch height of the foot on angular motion of  
347 the lower extremities in running. *J Biomech* 1993;26:909-16.
- 348 29. Winter DA. *Biomechanics and motor control of human movement*. 3rd ed. Hoboken, New  
349 Jersey: John Wiley & Sons, Inc.; 2005.
- 350 30. DeVita P, Hortobagyi T. Age causes a redistribution of joint torques and powers during gait.  
351 *J Appl Physiol* 2000;88:1804-11.
- 352 31. Graf A, Judge JO, Ounpuu S, Thelen DG. The effect of walking speed on lower-extremity  
353 joint powers among elderly adults who exhibit low physical performance. *Arch Phys Med*  
354 *Rehabil* 2005;86:2177-83.
- 355 32. Winter DA, Patla AE, Frank JS, Walt SE. Biomechanical walking pattern changes in the fit  
356 and healthy elderly. *Phys Ther* 1990;70:340-7.
- 357 33. Cohen J. *Statistical power analysis for the behavioral sciences* 2nd ed. New York City:  
358 Routledge Academic; 1988.
- 359 34. Neptune RR, Kautz SA, Zajac FE. Contributions of the individual ankle plantar flexors to  
360 support, forward progression and swing initiation during walking. *J Biomech* 2001;34:1387-98.
- 361 35. Sawicki GS, Lewis CL, Ferris DP. It pays to have a spring in your step. *Exerc Sport Sci Rev*  
362 2009;37:130-8.
- 363 36. Judge JO, Davis RB, 3rd, Ounpuu S. Step length reductions in advanced age: The role of  
364 ankle and hip kinetics. *J Gerontol A Biol Sci Med Sci* 1996;51:M303-12.
- 365 37. Kaji R. Physiology of conduction block in multifocal motor neuropathy and other  
366 demyelinating neuropathies. *Muscle Nerve* 2003;27:285-96.

- 367 38. Motl RW, McAuley E, Wynn D, Suh Y, Weikert M, Dlugonski D. Symptoms and physical  
368 activity among adults with relapsing-remitting multiple sclerosis. *J Nerv Ment Dis*  
369 2010;198:213-9.
- 370 39. Motl RW, Arnett PA, Smith MM, Barwick FH, Ahlstrom B, Stover EJ. Worsening of  
371 symptoms is associated with lower physical activity levels in individuals with multiple sclerosis.  
372 *Mult Scler* 2008;14:140-2.
- 373 40. Romani A, Bergamaschi R, Candeloro E, Alfonsi E, Callieco R, Cosi V. Fatigue in multiple  
374 sclerosis: Multidimensional assessment and response to symptomatic treatment. *Mult Scler*  
375 2004;10:462-8.
- 376 41. Koch M, Uyttenboogaart M, van Harten A, Heerings M, De Keyser J. Fatigue, depression  
377 and progression in multiple sclerosis. *Mult Scler* 2008;14:815-22.

378

379



380 *Figure Legends*

381 **Figure 1:** Marker set from the frontal plane

382 **Figure 2:** A subject walking with one foot striking the force platform

383 **Figure 3:** Joint Torque figures which identify the gait variables used

384 **Figure 4:** Joint Power figures which identify the gait variables used

385

1 **Tables**

2 Table 1: Demographic information of study participants. P-value is indicated for independent t-  
 3 test between groups.

|             | MS Patients<br>(n = 32) | Healthy Controls<br>(n = 30) |                  |
|-------------|-------------------------|------------------------------|------------------|
|             | Sex 5 male, 27 female   | 8 male; 22 female            |                  |
| Age         | 46.3 ± 10.8 yrs         | 41.4 ± 12.2 yrs              | <i>p</i> = 0.097 |
| EDSS        | 2.6 ± 0.7               | -                            |                  |
| Height (cm) | 165.0 ± 6.7             | 170.6 ± 11.2                 | <i>p</i> = 0.021 |
| Mass (kg)   | 79.9 ± 18.5             | 76.9 ± 18.5                  | <i>p</i> = 0.535 |

4

5

6 **Table 2: Averaged scores for each fatigue scale and for each component of the Medical**  
 7 **Outcomes Short Form 36 Health Survey (SF-36) for MS patients.**

| <i>Questionnaire Scale</i> | <i>MS patient score</i> |
|----------------------------|-------------------------|
|                            | mean $\pm$ SD           |
| Fatigue Severity           |                         |
| Scale                      | 4.6 $\pm$ 1.5           |
| Modified Fatigue           |                         |
| Impact Scale               | 42.3 $\pm$ 15.4         |
| SF-36                      |                         |
| Physical function          | 57.8 $\pm$ 23.6         |
| Limitation due to          |                         |
| Physical Function          | 43.0 $\pm$ 36.1         |
| Limitation due to          |                         |
| Emotional Problems         | 46.8 $\pm$ 43.0         |
| Energy                     | 46.4 $\pm$ 22.5         |
| Mental Health              | 65.0 $\pm$ 22.0         |
| Social Function            | 61.9 $\pm$ 27.3         |
| Bodily Pain                | 65.4 $\pm$ 22.9         |
| General Health             | 50.3 $\pm$ 20.6         |

9 **Table 3: Correlation matrix between quantitative parameters of gait mechanics (joint torques) and the qualitative self-**  
 10 **perceived measures of fatigue (Fatigue Severity Scale, Modified Fatigue Impact Scale) and functional status (SF-36) of MS**  
 11 **patients. Pearson correlation values are reported.**

| <i>Qualitative Measure</i>              | <i>Quantitative Measure</i> |                      |                      |                      |              |              |                      |
|---|-----------------------------|----------------------|----------------------|----------------------|--------------|--------------|----------------------|
|   | <b>d_Velocity</b>           | <b>d_ADT</b>         | <b>d_APT</b>         | <b>d_KET</b>         | <b>d_KFT</b> | <b>d_HET</b> | <b>d_HFT</b>         |
| FSS                                     | <b>*0.35 (.049)</b>         | 0.22                 | 0.31                 | 0.30                 | 0.09         | 0.26         | 0.02                 |
| MFIS                                    | 0.34                        | 0.20                 | 0.14                 | <b>*0.37 (.038)</b>  | -0.03        | 0.16         | -0.09                |
| SF-36                                   |                             |                      |                      |                      |              |              |                      |
| Physical function                       | <b>*-0.70 (.000)</b>        | <b>*-0.54 (.002)</b> | <b>*-0.51 (.003)</b> | <b>*-0.69 (.000)</b> | -0.15        | -0.22        | <b>*-0.39 (.029)</b> |
| Limitation due to<br>Physical Function  | <b>*-0.35 (.050)</b>        | -0.09                | -0.09                | -0.26                | 0.21         | -0.070       | -0.02                |
| Limitation due to<br>Emotional Problems | -0.11                       | 0.04                 | -0.22                | <b>*-0.36 (.041)</b> | 0.32         | -0.12        | -0.16                |
| Energy                                  | 0.05                        | 0.06                 | 0.18                 | -0.13                | 0.23         | -0.12        | 0.16                 |
| Mental Health                           | 0.13                        | 0.04                 | 0.12                 | -0.23                | 0.32         | -0.06        | 0.31                 |
| Social Function                         | -0.15                       | -0.08                | -0.08                | <b>*-0.37 (.038)</b> | 0.10         | -0.01        | 0.05                 |
| Bodily Pain                             | <b>*-0.46 (.008)</b>        | <b>*-0.37 (.037)</b> | -0.26                | <b>*-0.45 (.011)</b> | -0.15        | -0.03        | -0.13                |
| General Health                          | -0.11                       | -0.100               | -0.08                | -0.13                | 0.07         | -0.10        | 0.16                 |

12 SF-36: Medical Outcomes Survey Short Form 36 Health Survey.

13 \*Significant correlations (*p* -value).

14 d\_Velocity – difference in walking velocity; d\_ADT - difference in Peak ankle dorsiflexion moment during early stance; d\_APT -

15 difference in Peak ankle plantarflexion moment during late stance; d\_KFT - difference in Peak knee flexion moment during stance;

16 d\_KET - difference in Peak knee extension moment during stance; d\_HFT - difference in Peak hip flexion moment during late stance;

17 d\_HET - difference in Peak hip extension moment during early stance.

18 **Table 4: Correlation matrix between quantitative parameters of gait mechanics (joint powers) and the qualitative self-**  
 19 **perceived measures of fatigue (Fatigue Severity Scale, Modified Fatigue Impact Scale) and functional status (SF-36) of MS**  
 20 **patients. Pearson correlation values are reported.**

| <i>Qualitative Measure</i>              | <i>Quantitative Measure</i> |                     |                     |                     |                     |             |                    |             |
|---|-----------------------------|---------------------|---------------------|---------------------|---------------------|-------------|--------------------|-------------|
|   | <i>d_A1</i>                 | <i>d_A2</i>         | <i>d_K1</i>         | <i>d_K2</i>         | <i>d_K3</i>         | <i>d_H1</i> | <i>d_H2</i>        | <i>d_H3</i> |
| FSS                                     | 0.25                        | <b>0.42 (.010)</b>  | 0.28                | 0.27                | 0.31                | 0.31        | 0.07               | 0.00        |
| MFIS                                    | 0.31                        | 0.32                | <b>0.35 (.048)</b>  | 0.33                | 0.11                | 0.21        | 0.07               | 0.10        |
| SF-36                                   |                             |                     |                     |                     |                     |             |                    |             |
| Physical function                       | <b>-0.38(.033)</b>          | <b>-0.69 (.000)</b> | <b>-0.62 (.000)</b> | <b>-0.42 (.017)</b> | <b>-0.43 (.015)</b> | -0.11       | <b>-0.56(.001)</b> | 0.09        |
| Limitation due to<br>Physical Function  | -0.10                       | -0.23               | -0.24               | <b>-0.37 (.035)</b> | -0.29               | -0.17       | -0.10              | -0.17       |
| Limitation due to<br>Energonal Problems | -0.11                       | -0.28               | -0.29               | <b>-0.45 (.009)</b> | -0.19               | -0.04       | -0.28              | -0.22       |
| Energy                                  | -0.09                       | -0.01               | -0.08               | <b>-0.37 (.037)</b> | -0.15               | -0.03       | 0.06               | -0.24       |
| Mental Health                           | -0.06                       | 0.01                | -0.11               | -0.22               | -0.02               | -0.10       | 0.05               | -0.04       |
| Social Function                         | -0.18                       | -0.22               | -0.34               | <b>-0.38 (.030)</b> | -0.24               | -0.09       | -0.12              | -0.32       |
| Bodily Pain                             | -0.32                       | <b>-0.48 (.005)</b> | <b>-0.50 (.003)</b> | <b>-0.39 (.026)</b> | -0.14               | -0.13       | -0.27              | 0.14        |
| General Health                          | -0.01                       | -0.20               | -0.11               | -0.04               | -0.06               | -0.15       | -0.05              | 0.04        |

21 SF-36: Medical Outcomes Survey Short Form 36 Health Survey.

22 \*Significant correlations (*p* -value).

23 d\_A1 - difference in Peak ankle power absorption in early stance; d\_A2 - difference in Peak ankle power generation in late stance;


24 d\_K1 - difference in Peak knee power absorption in early stance; d\_K2 - difference in Peak knee power generation in mid-stance;

25 d\_K3 - difference in Peak knee power absorption in late stance; d\_H1 - difference in Peak hip power generation in early stance; d\_H2


26 - difference in Peak hip power absorption in late mid-stance; d\_H3 - difference in Peak hip power generation in late stance.




**Figure 1:** Marker set from the frontal plane



**Figure 2:** A subject walking with one foot striking the force platform



**Figure 3:** Joint Torque figures which identify the gait variables used



**Figure 4:** Joint Power figures which identify the gait variables used